Badreddin Edris - Jan 5, 2023 Form 4 Insider Report for SpringWorks Therapeutics, Inc. (SWTX)

Role: Chief Operating Officer
Signature: /s/ Francis I. Perier, Jr. as Attorney-in Fact
Stock symbol: SWTX
Transactions as of: Jan 5, 2023
Transactions value $: -$91,532
Form type: 4
Date filed: 1/9/2023, 04:01 PM
Previous filing: Jun 28, 2022
Next filing: Jun 14, 2023

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	SWTX	Common Stock	Award		+34K	+16.34%		242K	Jan 5, 2023	Direct	F1
transaction	SWTX	Common Stock	Tax liability	-$91.5K	-3.33K	-1.37%	$27.52	239K	Jan 6, 2023	Direct	F2, F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	SWTX	Stock Option (Right to Buy)	Award	$0	+105K		$0.00	105K	Jan 5, 2023	Common Stock	105K	$27.64	Direct	F4
transaction	SWTX	Stock Option (Right to Buy)	Award	$0	+135K		$0.00	135K	Jan 5, 2023	Common Stock	135K	$27.64	Direct	F5

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	This transaction represents a grant of restricted stock units ("RSUs"). The RSUs shall vest as follows: thirty three percent (33%) to vest on January 5, 2024, another thirty three percent (33%) to vest on January 5, 2025 and the remaining thirty four percent (34%) to vest on January 5, 2026, such that the restricted stock awards are fully vested on January 5, 2026.
F2	Represents shares withheld by the Issuer to satisfy tax withholding obligations in connection with the vesting of restricted stock units and does not represent a sale by the Reporting Person.
F3	Reflects a correction to the total number of securities beneficially owned, previously reported on a Form 4/A filed on January 14, 2022.
F4	This option shall vest in 48 equal monthly installments subject to continued service to the Issuer by the Reporting Person.
F5	Twenty-five percent (25%) of this option shall vest and become exercisable on January 5, 2024, with the remaining seventy-five percent (75%) to vest in thirty-six (36) equal monthly installments thereafter subject to continued service to the Issuer by the Reporting Person.